Alsius Corp 10th Amended and Restated Investor Rights Agreement.



 Exhibit 10.10 
 TENTH AMENDED AND RESTATED 
 INVESTOR RIGHTS AGREEMENT 
 THIS TENTH AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENT (this “Agreement”), is entered into on September 2, 2004 among ALSIUS
CORPORATION, a California corporation (the “Company”), and certain investors in the Company listed on Exhibit A hereto (as it may be amended from time to time pursuant to the terms hereof) (“Investors”). 
 WITNESSETH: 
 WHEREAS, pursuant to the
Restated Articles (as defined in that certain Series F Preferred Stock Purchase Agreement, dated as of the date hereof, among the Company and such Investors named therein (the “Series F Agreement”)), the outstanding shares of Series C-1,
Series C-2 and Series D Preferred Stock have been reclassified into shares of Series C-D Preferred Stock; 
 WHEREAS, certain of the
Investors hold shares of the Company’s Common Stock, Series A, Series B, Series C-D, Series E and/or Series F Preferred Stock (the “Prior Parties”) and possess registration rights, information rights, rights of first refusal, and
other rights pursuant to that certain Ninth Amended and Restated Investor Rights Agreement, dated as of December 23, 2003, between the Company, such Investors and certain other shareholders of the Company (the “Ninth Restated
Agreement”); 
 WHEREAS, on the date hereof, CHANNEL Medical Partners, L.P. (“CHANNEL”), Canaan Equity II L.P., Canaan Equity
II L.P. (QP) and Canaan Equity II Entrepreneurs LLC (“Canaan”) and other existing Investors are purchasing Series F Preferred Stock of the Company pursuant to a Series F Agreement; 
 WHEREAS, it is a condition to the obligations of CHANNEL and Canaan that this Agreement be executed by the parties hereto, and the parties are willing to
execute, and to be bound by the provisions of, this Agreement; 
 WHEREAS, the undersigned Prior Parties desire to terminate the Ninth
Restated Agreement and to accept on behalf of themselves and all other Investors, the rights created pursuant hereto in lieu of the rights granted to them under the Ninth Restated Agreement; 
 WHEREAS, the Investors and the Company are executing this Agreement to, among other things, amend Section 2.3(b) of the Ninth Restated Agreement to
change the number of shares of Common Stock that may be issued to employees, officers, directors and consultants from 900,000,000 shares to 2,100,000 shares to reflect the 500-for-1 reverse split of the Company’s capital stock effected on
March 22, 2004 and an increase in the number of authorized shares reserved for issuance to employees, officers, directors and consultants, to amend Section 3.6 of the Ninth Restated Agreement to clarify the requirements to amend the
agreement, to reflect the reclassification of the Series C-1, Series C-2 and Series D Preferred Stock into Series C-D Preferred Stock, to make certain other changes to the Ninth Restated Agreement in connection with the sale of the Series F
Preferred Stock to CHANNEL and Canaan, and to make CHANNEL and Canaan parties to the Ninth Restated Agreement; and 
 WHEREAS, the Investors
executing this Agreement hold a majority of the shares held by all investors who are party to the Ninth Restated Agreement and a majority of the shares of Series C-D, Series E and Series F Preferred Stock or Common Stock issuable upon conversion
thereof, and therefore, have the power under Section 3.6 of the Ninth Restated Agreement to amend such agreement. 







 NOW, THEREFORE, in consideration of the mutual promises and covenants set forth herein, the parties to
the Ninth Restated Agreement hereby agree that the Ninth Restated Agreement shall be superseded and replaced in its entirety by this Agreement, and the parties hereto further agree as follows: 
 SECTION 1 
 REGISTRATION RIGHTS 
 1.1 Certain Definitions. As used in this Agreement, the following terms shall have the following respective meanings: 
 “Act” means the Securities Act of 1933, as amended. 
 “Bridge Notes” shall mean the convertible promissory notes made by the Company, dated April 30, 2003, in connection with a bridge financing of the Company of approximately $3,088,000 and the convertible
promissory notes made by the Company, dated November 20, 2003, in connection with a bridge financing of $500,000. 
 “Commission” shall mean the Securities and Exchange Commission or any other federal agency at the time administering the Act. 
 “Common Stock” shall mean common stock of the Company, no par value. 
 “Company” shall have the meaning
assigned to such term in the Preamble hereto. 
 “Holder” shall mean any person holding Registrable Securities (or securities
convertible into or exchangeable for Registrable Securities) to whom the rights under this Section 1 were granted directly from the Company and any person holding Registrable Securities (or securities convertible into or exchangeable for
Registrable Securities) to whom the rights under this Section 1 have been transferred in accordance with Section 1.10 hereof. 
 “Initiating Holders” shall have the meaning set forth in Section 1.2 hereof. 
 “Qualified IPO” shall mean
a firm underwritten public offering by the Company of its Common Stock, with net proceeds of at least $20,000,000 and with a price per share of at least $0.025 (adjusted for any stock splits, stock dividends or recapitalizations), prior to the
deduction of underwriting commissions and offering expenses. 
 “Registrable Securities” means (i) the Common Stock issued in
exchange for the common stock issued by Retroperfusion Systems, Inc. (“RSI”) upon conversion of the RSI Series B, Series C and Series D Preferred Stock and in exchange for the RSI Series E and Series F Preferred Stock, (ii) the Common
Stock issued upon exercise of the warrants issued under the Loan and Warrant Subscription Agreements dated on or about August 17, 1993, (iii) the Common Stock issued under the Loan and Warrant Subscription Agreements dated October 1994,
(iv) the Common Stock issued or issuable upon conversion of the Series A, Series B, Series C-D, Series E and Series F Preferred Stock (v) the Common Stock issuable upon conversion of the Warrants issued in connection with the Bridge Notes
and (vi) any Common Stock of the Company issued or issuable in respect of the above described securities upon any stock split, stock dividend, recapitalization, or similar event, or any Common Stock otherwise issued or issuable with respect to
the above described securities; provided, however, that shares of Common Stock or other securities shall not be treated as Registrable Securities for purposes of Section 1 hereof if they have been sold to or through a broker or dealer or
underwriter in a public distribution or a public securities transaction. 







 The terms “register,” “registered” and “registration” refer to a
registration effected by preparing and filing a registration statement in compliance with the Act, and the declaration or ordering of the effectiveness of such registration statement. 
 “Registration Expenses” shall mean all expenses, except as otherwise stated below, incurred by the Company in complying with Sections 1.2, 1.3
and 1.4 hereof, including, without limitation, all registration, qualification and filing fees, printing expenses, escrow fees, fees and disbursements of counsel for the Company, blue sky fees and expenses and the expense of any regular or special
audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company). 
 “Selling Expenses” shall mean all underwriting discounts, selling commissions and stock transfer taxes applicable to the securities registered
by the Holders. 
 “Series A Preferred Stock” shall mean the Series A Preferred Stock of the Company acquired pursuant to the
Series A Preferred Stock Subscription Agreements of various dates. 
 “Series B Preferred Stock” shall mean the Series B Preferred
Stock of the Company acquired pursuant to the Note Conversion Agreement dated May 31, 1996. 
 “Series C-D Preferred Stock”
shall mean the Series C-D Preferred Stock issued upon exchange of (i) the Series C-1 and Series C-2 Preferred Stock of the Company issued pursuant to the Series C-1 and Series C-2 Preferred Stock Purchase Agreement dated as of March 14,
1997, including 106,250 shares of Series C-1 Preferred Stock issued to Guidant Corporation in exchange for consulting services, (ii) 163,077 shares of Series C-2 Preferred Stock of the Company issued to Guidant Corporation pursuant to the
Termination Agreement and Release dated November 1, 1998 by and between the Company and Guidant Corporation (the “Termination and Release”), (iii) the Series C-2 Preferred Stock of the Company issued pursuant to the Series C-2
Agreement and (iv) the Series D Preferred Stock of the Company acquired pursuant to the Series D Preferred Stock Purchase Agreement dated as of May 17, 2000. 
 “Series E Preferred Stock” shall mean the Series E Preferred Stock of the Company acquired pursuant to the Series E Preferred Stock Purchase Agreement dated as of November 8, 2000, and the Series E
Preferred Stock Purchase Agreement dated as of July 17, 2002. 
 “Series F Preferred Stock” shall mean the Series F Preferred
Stock of the Company acquired pursuant to the Series F Preferred Stock Purchase Agreement, dated as of the date of December 23, 2003, or acquired pursuant to the Series F Preferred Stock Purchase Agreement dated as of the date of this
Agreement. 
 “Warrants” means those certain warrants to purchase Common Stock of the Company, dated April 30, 2003, issued to
the initial purchasers of the Bridge Notes. 
 1.2 Requested Registration. 
 (a) In case the Company shall receive at any time after the earlier of (i) September 1, 2004 and (ii) six (6) months after the
effective date of the first registration statement filed by the Company covering an offering of any of its securities to the public, a written request from Holders (“Initiating Holders”) that the Company effect any registration,
qualification or compliance with respect to at least forty percent (40%) of the Registrable Securities (or any lesser number of Registrable Securities if the anticipated 








 
aggregate offering price to the public from the proposed sale of such Registrable Securities, net of underwriting discounts and commissions, would exceed
$8,000,000), the Company will: 
 (i) promptly give written notice of the proposed registration, qualification or compliance to all other
Holders; and 
 (ii) as soon as practicable, use its best efforts to effect such registration, qualification or compliance (including,
without limitation, appropriate qualification under applicable blue sky or other state securities laws and appropriate compliance with applicable regulations issued under the Act and any other governmental requirements or regulations) as may be so
requested and as would permit or facilitate the sale and distribution of all or such portion of such Registrable Securities as are specified in such request, together with all or such portion of the Registrable Securities of any Holder or Holders
joining in such request as are specified in a written request received by the Company within twenty (20) days after receipt of such written notice from the Company; 
 provided, however, that the Company shall not be obligated to take any action to effect any such registration, qualification or compliance pursuant to this Section 1.2: 
 (A) In any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such
registration, qualification or compliance unless the Company is already subject to service in such jurisdiction and except as may be required by the Act; 
 (B) During the period starting with the date sixty (60) days prior to the Company’s estimated date of filing of, and ending on the date one hundred eighty (180) days immediately following the effective
date of, any registration statement pertaining to securities of the Company (other than a registration of securities in a Rule 145 transaction or with respect to an employee benefit plan), provided that the Company is actively employing in good
faith all reasonable efforts to cause such registration statement to become effective; 
 (C) After the Company has effected two such
registrations pursuant to this Section 1.2(a), and such registrations have been declared or ordered effective; or 
 (D) If the Company
shall furnish to such Holders a certificate signed by the Chairman of the Board of Directors of the Company stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its shareholders for a
registration statement to be filed at such time, then the Company’s obligation to use its best efforts to register, qualify or comply under this Section 1.2 shall be deferred for a period not to exceed ninety (90) days from the date
of receipt of written request from the Initiating Holders; provided, however, the Company may only defer one registration pursuant to this Section 1.2(a)(ii)(D) in any twelve month period. 
 Subject to the foregoing clauses (A) through (D), the Company shall file a registration statement covering the Registrable Securities so requested
to be registered as soon as practicable, after receipt of the request or requests of the Initiating Holders. 
 (b) In the event that a
registration pursuant to Section 1.2 is for a registered public offering involving an underwriting, the Company shall so advise the Holders as part of the notice given pursuant to Section 1.2(a)(i). In such event, the right of any Holder
to registration pursuant to Section 1.2 shall be conditioned upon such Holder’s participation in the underwriting 








 
arrangements required by this Section 1.2, and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent requested
shall be limited to the extent provided herein. 
 The Company shall (together with all Holders proposing to distribute their securities
through such underwriting) enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by a majority in interest of the Initiating Holders, but subject to the Company’s reasonable
approval. Notwithstanding any other provision of this Section 1.2, if the managing underwriter advises the Initiating Holders in writing that marketing factors require a limitation of the number of shares to be, underwritten, then the Company
shall so advise all holders of Registrable Securities and the number of shares of Registrable Securities that may be included in the registration and underwriting shall be allocated among all Holders who have elected to participate in the
registration (except those Holders who have indicated to the Company their decision not to distribute any of their Registrable Securities through such underwriting) in proportion, as nearly as practicable, to the respective amounts of Registrable
Securities held by such Holders at the time of filing the registration statement. No Registrable Securities excluded from the underwriting by reason of the underwriter’s marketing limitation shall be included in such registration. To facilitate
the allocation of shares in accordance with the above provisions, the Company or the underwriters may round the number of shares allocated to any Holder to the nearest 100 shares. 
 If any Holder of Registrable Securities disapproves of the terms of the underwriting, such person may elect to withdraw therefrom by written notice to
the Company, the managing underwriter and the Initiating Holders. In the event of any such withdrawal, the participating Holders may increase their participation pro rata up to the amount equal to the withdrawn securities. 
 1.3 Company Registration. 
 (a) If at any
time or from time to time the Company shall determine to register any of its securities, either for its own account or the account of a security holder or holders, other than (i) a registration relating solely to employee benefit plans, or
(ii) a registration relating solely to a Commission Rule 145 transaction, the Company will: 
 (i) promptly give to each Holder written
notice thereof; and 
 (ii) include in such registration (and any related qualification under blue sky laws or other compliance), and in any
underwriting involved therein, all the Registrable Securities specified in a written request or requests, made within twenty (20) days after receipt of such written notice from the Company, by any Holder. 
 (b) If the registration of which the Company gives notice is for a registered public offering involving an underwriting, the Company shall so advise the
Holders as a part of the written notice given pursuant to Section 1.3(a)(i). In such event the right of any Holder to registration pursuant to Section 1.3 shall be conditioned upon such Holder’s participation in such underwriting and
the inclusion of Registrable Securities in the underwriting to the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall (together with the Company and the other holders distributing their
securities through such underwriting) enter into an underwriting agreement in customary form with the managing underwriter selected for such underwriting by the Company. Notwithstanding any other provision of this Section 1.3, if the managing
underwriter determines that marketing factors require a limitation of the number of shares to be underwritten, the managing underwriter may limit the Registrable Securities or other securities to be included in such registration, provided, however,
that after the Company’s 








 
initial firm commitment underwritten public offering (the “IPO”) no such limitation shall reduce the percentage of Registrable Securities included
in such registration below fifty percent (50%). In the Company’s IPO, such limitation may reduce the percentage of Registrable Securities included in such registration to 0%. The Company shall so advise all Holders and other holders
distributing their securities through such underwriting and the number of shares of Registrable Securities and other securities that may be included in the registration and underwriting shall be allocated among all Holders and such other holders in
proportion, as nearly as practicable, to the respective amounts of Registrable Securities and other securities contractually entitled to registration in the offering held by such Holders and such other holders at the time of filing the registration
statement. To facilitate the allocation of shares in accordance with the above provisions, the Company may round the number of shares allocated to any Holder or holder to the nearest 100 shares. If any Holder or holder disapproves of the terms of
any such underwriting, he may elect to withdraw therefrom by written notice to the Company and the managing underwriter. In the event of any such withdrawal, the participating Holders may increase their participation pro rata up to the amount equal
to the withdrawn securities. 
 (c) The Company shall have the right to terminate or withdraw any registration initiated by it under this
Section 1.3 prior to the effectiveness of such registration whether or not any Holder has elected to include securities in such registration. 
 1.4 Registration on Form S-3. 
 (a) If any Holder or Holders request that the Company file a registration statement on Form S-3 (or
any successor form to Form S-3) for a public offering of shares of the Registrable Securities the reasonably anticipated aggregate price to the public of which, net of underwriting discounts and commissions, would exceed $1,000,000, and the Company
is a registrant entitled to use Form S-3 to register the Registrable Securities for such an offering, the Company shall use its best efforts to cause such Registrable Securities to be registered for the offering on such form and to cause such
Registrable Securities to be qualified in such jurisdictions as the Holder or Holders may reasonably request; provided, however, that the Company shall not be required to effect more than one registration pursuant to this Section 1.4 in any
twelve (12) month period. In the event that a registration statement pursuant to this Section 1.4 is for a registered public offering involving an underwriting, the substantive provisions of Section 1.2(b) shall be applicable to such
registration initiated under this Section 1.4. 
 (b) Notwithstanding the foregoing, the Company shall not be obligated to take any
action pursuant to this Section 1.4: (i) in any particular jurisdiction in which the Company would be required to execute a general consent to service of process in effecting such registration, qualification or compliance unless the
Company is already subject to service in such jurisdiction and except as may be required by the Act; (ii) if the Company, within ten (10) days of the receipt of the request of the Initiating Holders, gives notice of its bona fide intention
to effect the filing of a registration statement with the Commission within forty-five (45) days of receipt of such request (other than with respect to a registration statement relating to a Rule 145 transaction, an offering solely to employees
or any other registration which is not appropriate for the registration of Registrable Securities); provided that the Company is actively employing in good faith all reasonable efforts to cause such registration statement to become effective and the
Registrable Securities which are the subject of the requested registration will be included in such Company initiated registration; or (iii) if the Company shall furnish to such Holder a certificate signed by the Chairman of the Board of
Directors of the Company stating that in the good faith judgment of the Board of Directors it would be seriously detrimental to the Company or its shareholders for a registration statement to be filed at such time, then the Company’s obligation









 
to use its best efforts to file a registration statement shall be deferred for a period not to exceed ninety (90) days from the receipt of the request
to file such registration by such Holder; provided, however, the Company may only defer one registration pursuant to this Section 1.4(b) in any twelve month period. 
 1.5 Expenses of Registration. All Registration Expenses, excluding underwriting discounts and commissions, incurred in connection with any registration effected pursuant to the terms of Section 1.2, 1.3 and 1.4
hereof, shall be borne by the Company. 
 However, if any Holder elects to withdraw from an underwriting under Section 1.2 or 1.4, then that Holder
shall be responsible for all of its Registration Expenses for that particular registration. All Selling Expenses relating to securities registered on behalf of the Holders and all other registration expenses shall be borne by the Holders of such
securities pro rata on the basis of the number of shares so registered. 
 1.6 Registration Procedures. In the case of each registration,
qualification or compliance effected by the Company pursuant to this Section 1, the Company will keep each Holder advised in writing as to the initiation of each registration, qualification and compliance and as to the completion thereof. At
its expense the Company will: 
 (a) Prepare and file with the Commission a registration statement with respect to such securities and use
its best efforts to cause such registration statement to become and remain effective for at least one hundred twenty (120) days or until the distribution described in the Registration Statement has been completed; provided, however, in the case
of any registration of Registrable Securities on Form S-3 which are intended to be offered on a continuous or delayed basis, such one hundred twenty (120) day period shall be extended, if necessary, to keep the registration statement effective
until all such Registrable Securities are sold, provided that Rule 415, or any successor rule under the Act, permits an offering on a continuous or delayed basis, and provided further that applicable rules under the Act governing the obligation to
file a post-effective amendment permit, in lieu of filing a post-effective amendment that (A) includes any prospectus required by section 10(a)(3) of the Act or (B) reflects facts or events representing a material or fundamental change in
the information set forth in the registration statement, the incorporation by reference of information required to be included in (A) and (B) above to be contained in periodic reports filed pursuant to section 13 or 15(d) of the Exchange
Act (as defined below) in the registration statement. 
 (b) As promptly as practicable, prepare and file with the Commission such
amendments and supplements to such registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Act with respect to the disposition of all securities covered
by such registration statement. 
 (c) Furnish to the Holders such numbers of copies of a prospectus, including a preliminary prospectus, in
conformity with the requirements of the Act, and such other documents as they may reasonably request in order to facilitate the disposition of Registrable Securities owned by them. 
 (d) Use its best efforts to register and qualify the securities covered by such registration statement under such other securities or Blue Sky laws of
such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any
such states or jurisdictions. 
 (e) In the event of any underwritten public offering, enter into and perform its obligations under an
underwriting agreement, in usual and 








 
customary form, with the managing underwriter of such offering. Each Holder participating in such underwriting shall also enter into and perform its
obligations under such an agreement. 
 (f) Notify each Holder of Registrable Securities covered by such registration statement at any time
when a prospectus relating thereto is required to be delivered under the Act of the happening of any event as a result of which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material
fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing and as soon as practicable thereafter, prepare and furnish to each Holder
a reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of such shares, such prospectus shall not include an untrue statement of a material fact or
omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading or incomplete in the light of the circumstances then existing. 
 (g) Cause all such Registrable Securities registered pursuant hereunder to be listed on each securities exchange on which similar securities issued by
the Company are then listed. 
 (h) Provide a transfer agent and registrar for all Registrable Securities registered pursuant to such
registration statement and a CUSIP number for all such Registrable Securities, in each case not later than the effective date of such registration. 
 (i) Use its best efforts to comply with all applicable rules and regulations of the Commission, and make available to its security holders, as soon as reasonably practicable, an earnings statement covering the period
of at least twelve (12) months, but not more than eighteen (18) months, beginning with the first month after the effective date of any registration statement, which earnings statement shall satisfy the provisions of section 11(a) of the
Act. 
 (j) Furnish, at the request of any Holder requesting registration of Registrable Securities pursuant to this Section 1, on the
date that such Registrable Securities are delivered to the underwriters for sale in connection with a registration pursuant to this Section 1, (i) an opinion, dated such date, of the counsel representing the Company for the purposes of
such registration, in form and substance as is customarily given to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities and (ii) a letter
dated such date, from the independent accountants of the Company, in form and substance as is customarily given by independent accountants to underwriters in an underwritten public offering, addressed to the underwriters, if any, and to the Holders
requesting registration of Registrable Securities. 
 1.7 Indemnification. 
 (a) The Company will indemnify each Holder, each of its officers and directors and partners, and each person controlling such Holder within the meaning
of section 15 of the Act, with respect to which registration, qualification or compliance has been effected pursuant to this Section 1, and each underwriter, if any, and each person who controls any underwriter within the meaning of section 15
of the Act, against all expenses, claims, losses, damages or liabilities (or actions in respect thereof), including any of the foregoing incurred in settlement of any litigation, commenced or threatened, arising out of or based on any untrue
statement (or alleged untrue statement) of a material fact contained in any registration statement, prospectus, offering circular or other document, or any amendment or supplement thereto, incident to any such registration, 








 
qualification or compliance, or based on any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances in which they were made, not misleading, or any violation by the Company of any federal, state or common law rule or regulation applicable to the Company in connection with any such
registration, qualification or compliance, and the Company will reimburse each such Holder, each of its officers and directors, and each person controlling such Holder, each such underwriter and each person who controls any such underwriter, for any
legal and any other expenses reasonably incurred in connection with investigating, preparing or defending any such claim, loss, damage, liability or action, provided that the Company will not be liable in any such case to the extent that any such
claim, loss, damage, liability or expense arises out of or is based on any untrue statement or omission or alleged untrue statement or omission, made in reliance upon and in conformity with written information furnished to the Company by an
instrument duly executed by such Holder, controlling person or underwriter and stated to be specifically for use therein. 
 (b) Each Holder
will, if Registrable Securities held by such Holder are included in the securities as to which such registration, qualification or compliance is being effected, indemnify the Company, each of its directors and officers, each underwriter, if any, of
the Company’s securities covered by such a registration statement, each person who controls the Company or such underwriter within the meaning of section 15 of the Act, and each other such Holder, each of its officers and directors and each
person controlling such Holder within the meaning of section 15 of the Act, against all claims, losses, damages and liabilities (or actions in respect thereof) arising out of or based on any untrue statement (or alleged untrue statement) of a
material fact contained in any such registration statement, prospectus, offering circular or other document, or any omission (or alleged omission) to state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading, and will reimburse the Company, such Holders, such directors, officers, persons, underwriters or control persons for any legal or any other expenses reasonably incurred in connection with investigating or defending any such
claim, loss, damage, liability or action, in each case to the extent, but only to the extent, that such untrue statement (or alleged untrue statement) or omission (or alleged omission) is made in such registration statement, prospectus, offering
circular or other document in reliance upon and in conformity with written information furnished to the Company by an instrument duly executed by such Holder and stated to be specifically for use therein. Notwithstanding the foregoing, the liability
of each Holder under this subsection (b) shall be limited in an amount equal to the public offering price of the shares sold by such Holder. A Holder will not be required to enter into any agreement or undertaking in connection with any
registration under this Section 1.7 providing for any indemnification or contribution on the part of such Holder greater than the Holder’s obligations under this Section 1.7(b). 
 (c) Each party entitled to indemnification under this Section 1.7 (the “Indemnified Party”) shall give notice to the party required to
provide indemnification (the “Indemnifying Party”) promptly after such Indemnified Party has actual knowledge of any claim as to which indemnity may be sought, and shall permit the Indemnifying Party to assume the defense of any such claim
or any litigation resulting therefrom, provided that counsel for the Indemnifying Party, who shall conduct the defense of such claim or litigation, shall be approved by the Indemnified Party (whose approval shall not unreasonably be withheld), and
the Indemnified Party may participate in such defense at such party’s expense, provided, however, that the Indemnifying Party shall bear the expense of independent counsel for the Indemnified Party if the Indemnified Party reasonably determines
that representation of both parties by the same counsel would be inappropriate due to actual or potential conflicts of interest, and provided further that the failure of any Indemnified Party to give notice as provided herein shall not relieve the
Indemnifying Party of its obligations 








 
under this Section 1.7 unless the failure to give such notice is materially prejudicial to an Indemnifying Party’s ability to defend such action
and provided further, that the Indemnifying Party shall not assume the defense for matters as to which there is a conflict of interest or separate and different defenses. No Indemnifying Party, in the defense of any such claim or litigation, shall,
except with the consent of each Indemnified Party, consent to entry of any judgment or enter into any settlement which does not include as an unconditional term thereof the giving by the claimant or plaintiff to such Indemnified Party of a release
from all liability in respect to such claim or litigation. 
 1.8 Information by Holder. The Holder or Holders of Registrable Securities
included in any registration shall furnish to the Company such information regarding such Holder or Holders, the Registrable Securities held by them and the distribution proposed by such Holder or Holders as the Company may request in writing and as
shall be required in connection with any registration, qualification or compliance referred to in this Section 1. 
 1.9 Rule 144
Reporting. With a view to making available the benefits of certain rules and regulations of the Commission which may at any time permit the sale of the Restricted Securities to the public without registration, after such time as a public market
exists for the Common Stock of the Company, the Company agrees to use its best efforts to: 
 (a) Make and keep public information available,
as those terms are understood and defined in Rule 144 under the Act, at all times after the effective date that the Company becomes subject to the reporting requirements of the Act or the Securities Exchange Act of 1934, as amended (the
“Exchange Act”). 
 (b) Use its best efforts to file with the Commission in a timely manner all reports and other documents
required of the Company under the Act and the Exchange Act (at any time after it has become subject to such reporting requirements); 
 (c)
So long as a Holder owns any Registrable Securities that are “restricted securities” under Rule 144 under the Act, to furnish to the Holder forthwith upon request a written statement by the Company as to its compliance with the reporting
requirements of said Rule 144 (at any time after ninety (90) days after the effective date of the first registration statement filed by the Company for an offering of its securities to the general public), and of the Act and the Exchange Act
(at any time after it has become subject to such reporting requirements), a copy of the most recent annual or quarterly report of the Company, and such other reports and documents of the Company and other information in the possession of or
reasonably obtainable by the Company as a Holder may reasonably request in availing itself of any rule or regulation of the Commission allowing a Holder to sell any such securities without registration. 
 1.10 Transfer of Registration Rights. The rights to cause the Company to register securities granted Investor under Sections 1.2, 1.3 and 1.4 may be
assigned to a transferee or assignee in connection with any transfer or assignment of Registrable Securities by an Investor provided that: (a) such transfer may otherwise be effected in accordance with applicable securities laws, and
(b) such assignee or transferee acquires at least 50,000 shares of Registrable Securities (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits’, and the like and
aggregating all shares of Registrable Securities held by entities affiliated with an Investor, including but not limited to trusts for the benefit of an Investor or Investor’s immediate family members and any partners of an Investor) or the
securities into which they are convertible. Notwithstanding the foregoing, the rights to cause the Company to register securities may be assigned, in connection with a distribution by such Investor, to any partner, former partner, affiliate or the
estate of any such partner without compliance with item (b) above, provided written notice thereof is promptly given to the Company. 







 1.11 Standoff Agreement. Each Holder agrees, so long as such Holder holds at least one percent
(1%) of the Company’s outstanding voting equity securities, in connection with an underwritten public offering of the Company’s securities that, upon request of the Company or the underwriters managing any underwritten offering of the
Company’s securities, not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any Common Stock of the Company (other than those included in the registration) without the prior written consent of
the Company or such underwriters, as the case may be, for such period of time (not to exceed one hundred eighty (180) days in the case of a Qualified IPO and not to exceed ninety (90) days, or one hundred twenty (120) days if the
Holder holds ten percent (10%) of the outstanding stock of the Company, in the case of any other public offering) from the effective date of such registration as may be requested by the underwriters; provided, that all other Holders of at least
one percent (1%) of the Company’s outstanding voting equity securities and all of the officers and directors of the Company who own stock of the Company also agree to such restrictions. 
 1.12 Termination of Registration Rights. No Holder of Registrable Securities shall be entitled to exercise any right provided in this Section 1
after five (5) years following the consummation of a Qualified IPO if such Holder can sell its securities under Rule 144, or any successor rule, without any restriction on volume. 
 SECTION 2 
 COVENANTS OF THE COMPANY 
 2.1 Basic Financial Information. The Company will furnish the following reports to each Holder of at least 400 shares (as presently constituted and
subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like and aggregating all shares of Registrable Securities held by entities affiliated with an Investor, including but not limited to trusts for the
benefit of an Investor or Investor’s immediate family members and any partner of an Investor) of the Company’s Registrable Securities (each a “Significant Holder”): 
 (a) As soon as practicable after the end of each fiscal year of the Company, and in any event within ninety (90) days thereafter, a consolidated
balance sheet of the Company and its subsidiaries, if any, as at the end of such fiscal year, and consolidated statements of income and cash flows of the Company and its subsidiaries, if any, for such year, prepared in accordance with generally
accepted accounting principles consistently applied and setting forth in each case in comparative form the figures for the previous fiscal year, all in reasonable detail and certified by independent public accountants of recognized national standing
selected by the Company. 
 (b) As soon as practicable after the end of the first, second, and third quarterly accounting periods in each
fiscal year of the Company, and in any event within forty-five (45) days thereafter, a consolidated balance sheet of the Company and its subsidiaries, if any, as of the end of each such quarterly period, and consolidated statements of income
and cash flows of the Company and its subsidiaries for such period and for the current fiscal year to date, prepared in accordance with generally accepted accounting principles consistently applied and setting forth in comparative form the figures
for the corresponding periods of the previous fiscal year and to the Company’s operating plan then in effect and approved by its Board of Directors, subject to changes resulting from normal year-end audit adjustments, all in reasonable detail
and certified by the principal financial or accounting officer of the Company, except that such financial statements need not contain the notes required by generally accepted accounting principles. 







 (c) From the date the Company becomes subject to the reporting requirements of the Exchange Act (which
shall include any successor federal statute), and in lieu of the financial information required pursuant to Sections 2.1(a) and (b), copies of its annual reports on Form 10-K and its quarterly reports on Form 10-Q, respectively. 
 2.2 Additional Information Rights. 
 (a) The
Company will deliver the following reports and other information to each Significant Holder: 
 (i) As soon as practical after the end of
each month and in any event within thirty (30) days thereafter a consolidated balance sheet of the Company and its subsidiaries, if any, as at the end of such month and consolidated statements of income and cash flows of the Company and its
subsidiaries, for each month and for the current fiscal year of the Company to date, all subject to normal year-end audit adjustments, prepared in accordance with generally accepted accounting principles consistently applied and certified by the
principal financial or accounting officer of the Company, together with a comparison of such statements to the corresponding periods of the prior fiscal year and to the Company’s operating plan then in effect and approved by its Board of
Directors. 
 (ii) Annually (but in any event at least thirty (30) days prior to the commencement of each fiscal year of the Company)
the financial plan of the Company, in such manner and form as approved by the Board of Directors of the Company, which financial plan shall include a projection of income and a projected cash flow statement for such fiscal year and a projected
balance sheet as of the end of such fiscal year. Any material changes in such business plan shall be delivered to each Significant Holder as promptly as practicable after such changes have been approved by the Board of Directors of the Company.

 (iii) As soon as practicable after each meeting of the Company’s Board of Directors, and in any event within thirty (30) days
thereafter, a complete and accurate copy of the minutes of such meeting as recorded by the Secretary of the Company. 
 (iv) With reasonable
promptness, such other information and data with respect to the Company and its subsidiaries that has been furnished to the Company’s Board of Directors. 
 (b) The provisions of Section 2.1 and this Section 2.2 shall not be in limitation of any rights which any Holder or Significant Holder may have with respect to the books and records of the Company and its
subsidiaries, or to inspect their properties or discuss their affairs, finances and accounts, under the laws of the jurisdictions in which they are incorporated. 
 (c) Anything in Section 2 to the contrary notwithstanding, no Holder or Significant Holder by reason of this Agreement shall have access to any trade secrets or classified information of the Company. Each
Significant Holder hereby agrees to hold in confidence and trust and not to misuse or disclose any confidential information provided pursuant to this Section 2. The Company shall not be required to comply with this Section 2.2 in respect
of any Holder whom the Company reasonably determines to be a competitor or an officer, employee, director or greater than ten percent (10%) shareholder of a competitor. 
 (d) Each Holder who represents to the Company that it is a “venture capital operating company” for purposes of Department of Labor Regulation
Section 2510.3-101 shall in addition have the right to consult with and advise the officers of the Company as to the management of the Company. 







 2.3 Right of Participation. 
 (a) The Company hereby grants to each Investor holding at least 400 shares (as presently constituted and subject to subsequent adjustments for stock
splits, stock dividends, reverse stock splits, and the like and aggregating all shares of Registrable Securities held by entities affiliated with an Investor, including but not limited to family members of an Investor, trusts for the benefit of an
Investor or Investor’s immediate family members and any partner of an Investor) of the Company’s Registrable Securities the right of participation to purchase up to its Pro Rata Share, as defined below, of New Securities (as defined in
Section 2.3(b)) which the Company may, from time to time, propose to sell and issue. An Investor’s Pro Rata Share, for purposes of this right of participation, is the ratio that the number of shares of Common Stock issued or issuable upon
conversion of the Registrable Securities held by such Investor bears to the sum of the total shares of issued and outstanding Common Stock of the Company, including shares of Common Stock issuable upon conversion of outstanding capital stock or
other convertible securities other than options or warrants. 
 (b) Except as set forth below, “New Securities” shall mean any
shares of capital stock of the Company including Common Stock and Preferred Stock, whether now authorized or not, and rights, options or warrants to purchase said shares of Common Stock or Preferred Stock, and securities of any type whatsoever that
are, or may become, convertible into said shares of Common Stock or Preferred Stock. Notwithstanding the foregoing, “New Securities” shall not include (a) securities issued pursuant to the acquisition of another corporation by the
Company by merger, purchase of substantially all of the assets or other reorganization whereby the Company or its shareholders own not less than fifty-one percent (51%) of the voting power of the surviving or successor corporation, (b) shares
of the Company’s Common Stock or securities convertible into Common Stock or related options or warrants exercisable for or convertible into such Common Stock or securities convertible into Common Stock issued to employees, officers and
directors of, and consultants pursuant to a plan approved by the Board of Directors of the Company up to an aggregate of 2,100,000 shares (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse
stock splits, and the like), (c) up to five percent (5%) of outstanding capital stock of the Company on a fully diluted basis issued to customers, vendors, licensees, licensors, and equipment lessors of the Company, pursuant to any
arrangement approved by the Board of Directors of the Company, (d) shares issued upon conversion of shares of Series A, Series B, Series C-D, Series E or Series F Preferred Stock, (e) shares issued in connection with any stock split or
recapitalization by the Company, (f) shares issued as a dividend or distribution on Series A, Series B, Series C-D, Series E or Series F Preferred Stock or (g) shares of Series C-D Preferred Stock issued in connection with the
reclassification of the Series C-1, Series C-2 and Series D Preferred Stock. 
 (c) In the event the Company proposes to undertake an
issuance of New Securities, it shall give each Investor written notice of its intention, describing the type of New Securities, and the price and terms upon which the Company proposes to issue the same. Each Investor shall have fifteen
(15) days from the date of receipt of any such notice to agree to purchase up to its respective Pro Rata Share of such New Securities for the price and upon the terms specified in the notice by giving written notice to the Company and stating
therein the maximum quantity of New Securities it will agree to purchase. 
 (d) In the event an Investor fails to exercise the right of
participation to purchase its Pro Rata Share of such New Securities within said fifteen (15) day period, the Company shall offer such shares to the other Investors who have elected to exercise their rights to purchase New Securities. Each such
participating Investor shall be entitled to purchase that number of 








 
shares of new securities not being purchased by the non-participating Investor as determined by multiplying such non-purchased New Securities by a fraction,
the numerator of which is the number of shares of New Securities being purchased by the participating Investor and the denominator of which is the number of shares of New Securities being purchased by all Investors electing to purchase a portion of
the New Securities which would have been sold to the non-participating Investor. Each Investor electing to purchase such non-participating Investor’s New Securities shall have five (5) days from the date of receipt of any notice from the
Company with respect thereto to agree to purchase its respective share of such non-participating Investor’s New Securities. Thereafter, the Company shall have ninety (90) days thereafter to sell or enter into an agreement (pursuant to
which the sale of New Securities covered thereby shall be closed, if at all, within sixty (60) days from the date of said agreement) to sell the New Securities not elected to be purchased by Investors at the price and upon the terms no more
favorable to the purchasers of such securities then specified in the Company’s notice. In the event the Company has not sold the New Securities or entered into an agreement to sell the New Securities within said ninety (90) day period (or
sold and issued New Securities in accordance with the foregoing within sixty (60) days from the date of said agreement), the Company shall not thereafter issue or sell any New Securities, without first offering such securities in the manner
provided above. 
 (e) The right of participation granted under this Agreement shall expire (a) upon the closing of and does not apply
to shares issued in connection with a Qualified IPO and (b) as to each Investor if such Investor (along with affiliated entities of such Investor) no longer holds 400 shares of Registrable Securities (as presently constituted and subject to
subsequent adjustments for stock splits, stock dividends, reverse stock splits, and the like). 
 (f) The right of participation hereunder
may be assigned to a transferee or assignee in connection with any transfer or assignment of Registrable Securities by an Investor provided that: (a) such transfer may otherwise be effected in accordance with applicable securities laws, and
(b) such assignee or transferee acquires at least 50,000 shares of Registrable Securities (as presently constituted and subject to subsequent adjustments for stock splits, stock dividends, reverse stock splits’, and the like and
aggregating all shares of Registrable Securities held by entities affiliated with an Investor, including but not limited to trusts for the benefit of an Investor or Investor’s immediate family members and any partners of an Investor) or the
securities into which they are convertible. Notwithstanding the foregoing, the rights to cause the Company to register securities may be assigned, in connection with a distribution by such Investor, to any partner, former partner, affiliate or the
estate of any such partner without compliance with item (b) above, provided written notice thereof is promptly given to the Company. 
 2.4 Treatment of Investors. 
 (a) No Investor will be offered (either directly or indirectly) any consideration or other rights in
connection with any amendment, waiver or consent of or under the Company’s articles of incorporation which is not offered to all Investors similarly situated. 
 (b) No Investor will be offered (either directly or indirectly) any consideration or other rights, except as currently provided under the Ancillary Agreements (as defined in the Series F Agreement), in connection with
any amendment or waiver of this Agreement which is not offered to all Investors similarly situated. 







 SECTION 3 
 MISCELLANEOUS 
 3.1 Successors and Assigns. The terms and conditions of this Agreement shall inure to the
benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any
rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 
 3.2
Governing Law. This Agreement shall be governed by and construed under the laws of the State of California as applied to agreements among California residents entered into and to be performed entirely within California. 
 3.3 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. 
 3.4 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience
only and are not to be considered in construing or interpreting this Agreement. 
 3.5 Notices. Unless otherwise provided, any notice
required or permitted under this Agreement shall be given in writing and shall be deemed effectively given upon personal delivery to the party to be notified by hand or professional courier service, by facsimile upon receipt of confirmation of
delivery or five (5) days after deposit with the United States Post Office, by registered or certified mail, postage prepaid and addressed to the party to be notified at the Company’s addressed in the case of the Company, or for the
Investors, at the address indicated on Exhibit A, or at such other address as such party may designate by ten (10) days’ advance written notice to the other parties. 
 3.6 Amendment and Waivers. Except as may be otherwise provided in Section 3.7, any provision of this Agreement may be amended and the observance
thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), with the written consent of the Company, the Investors holding a majority of the shares held by all Investors, and the Investors holding
a majority of the shares of Common Stock issued or issuable upon conversion of Series C-D, Series E and Series F Preferred Stock; provided, however, that any waiver or amendment that adversely affects an Investor in a manner that is materially
different than the other Investors (other than differences resulting solely from ownership of a different amount of shares) shall require the written consent of such Investor in order to be binding on such Investor; and, provided further, that the
Company may amend Exhibit A to this Agreement at any time and from time to time without the consent of any Investor solely to (i) add CHANNEL and any Rights Investor (as defined in the Purchase Agreement), in each case provided that CHANNEL and
such Rights Investor executes a Counterpart to this Agreement in the form of Exhibit B hereto as a party to this Agreement, or (ii) reflect the conversion to Common Stock of the Preferred Stock of any Investor whose Preferred Stock is so
converted (voluntarily or automatically) pursuant to the conversion provisions of such Preferred Stock, or to reflect any adjustment to the outstanding shares of Preferred Stock or Common Stock due to a stock split, stock dividend or
recapitalization. Any amendment or waiver effected in accordance with this Section shall be binding upon all present and future Investors. 
 3.7 Additional Registration Rights. The Company will not grant any registration rights not set forth herein without the prior approval of the Holders of more than fifty percent (50%) of the then outstanding Registrable Securities and
the Investors holding a majority of the shares of Common Stock issued or issuable upon conversion of Series C-D, Series E and Series F Preferred Stock; provided, however, in the event the Shareholders of the Company have legally and validly approved
the sale of securities and the granting of registration rights to the holders thereof, such securities may be added to the definition of Registrable Securities hereunder and such holders shall constitute Holders hereunder to the extent they agree in
writing to be bound by the terms and conditions hereof. 
 3.8 Severability. If one or more provisions of this Agreement are held to be
unenforceable under applicable law, such provision shall be excluded from this Agreement and the balance of the Agreement shall be interpreted as if such provision were so excluded and shall be enforceable in accordance with its terms. 

3.9 Effect of Amendment or Waiver. Each Holder acknowledges that by the operation of Section 3.6 hereof less than all of the Holders (or
transferees of Registrable Securities) may effect an amendment or waiver of provisions of this Agreement and may therefore diminish or eliminate all rights of such Holder under this Agreement even though such Holder has not consented to the
amendment or waiver. 
 [SIGNATURES ON FOLLOWING PAGE] 








			
	THE COMPANY
	
	ALSIUS CORPORATION
		
	By	 	 /s/ William J. Worthen

	Title	 	President and Chief Executive Officer
		
	Address:	 	
	
	 15570 Laguna Canyon Road
 Suite
150
 Irvine, CA 92618











			
	INVESTORS:
	
	CANAAN EQUITY II L.P.
		
	By:	 	Canaan Equity Partners II LLC
		
	By:	 	 /s/ James C. Furnivall

		 	Member/Manager
		 	James C. Furnivall
		
	Address:	 	 105 Rowayton Avenue
 Rowayton, CT
06853

	
	CANAAN EQUITY II L.P. (QP)
		
	By:	 	Canaan Equity Partners II LLC
		
	By:	 	 /s/ James C. Furnivall

		 	Member/Manager
		 	James C. Furnivall
		
	Address:	 	 105 Rowayton Avenue
 Rowayton, CT
06853

	
	CANAAN EQUITY II ENTREPRENEURS LLC
		
	By:	 	Canaan Equity Partners II LLC
		
	By:	 	 /s/ James C. Furnivall

		 	Manager
		 	James C. Furnivall
		
	Address:	 	 105 Rowayton Avenue
 Rowayton, CT
06853











			
		 	 /s/ Dr. Seth Rudnick

		 	Dr. Seth Rudnick
		
	Address:	 	 Canaan Partners
 105 Rowayton Ave
 Rowayton, CT 06853

	
	Hutton Living Trust dated 12/10/96
		
	By:	 	 /s/ Wende Hutton

	Name:	 	Wende S. Hutton
	Title:	 	Trustee
		
	Address:	 	 2 Santiago Avenue
 Atherton, CA
94027

		
		 	 /s/ Gregory Kopchinsky

		 	Gregory Kopchinsky
		
	Address:	 	 Canaan Partners
 105 Rowayton Ave
 Rowayton, CT 06853











			
	CHANNEL MEDICAL PARTNERS, L.P.,
	a Delaware limited partnership
		
	By:	 	CHANNEL Medical Management, L.L.C.
	Its:	 	General Partner
		
	By:	 	CHANNEL Medical Advisors, Inc.
	Its:	 	Manager
		
	By:	 	 /s/ W. Gregory Shearer

		 	W. Gregory Shearer
		 	President
		
	Address:	 	 5750 Old Orchard Road
 Suite 310
 Skokie, IL 60077











			
	MAYFIELD VIII
		
	By:	 	 /s/ Harvey Schloss

	Name:	 	Harvey Schloss
	Title:	 	Authorized Signatory
		
	Address:	 	 2800 Sand Hill Road
 Menlo Park, CA
94025

	
	MAYFIELD ASSOCIATES FUND III
		
	By:	 	 /s/ Harvey Schloss

	Name:	 	Harvey Schloss
	Title:	 	Authorized Signatory
		
	Address:	 	 2800 Sand Hill Road
 Menlo Park, CA
94025

	
	FEVER TRUST
		
	By:	 	 /s/ James T. Beck

	Name:	 	James T. Beck
	Title:	 	Administrative Trustee
		
	Address:	 	 2800 Sand Hill Road
 Menlo Park, CA
94025

	
	FEVER TRUST II
		
	By:	 	 /s/ James T. Beck

	Name:	 	James T. Beck
	Title:	 	Administrative Trustee
		
	Address:	 	 2800 Sand Hill Road
 Menlo Park, CA
94025











			
	FEVER TRUST III
		
	By:	 	 /s/ James T. Beck

	Name:	 	James T. Beck
	Title:	 	Administrative Trustee
		
	Address:	 	 2800 Sand Hill Road
 Menlo Park, CA
94025











			
	NEW ENTERPRISE ASSOCIATES, VII, LIMITED PARTNERSHIP
		
	By:	 	NEA Partners VII, Limited
		 	Partnership
		 	Its General Partner
		
	By:	 	 /s/ C. Richard Kramlich

	Name:	 	C. Richard Kramlich
	Title:	 	General Partner
		
	Address:	 	 2800 Sand Hill Road
 Menlo Park, CA
94025

	
	NEA PRESIDENTS FUND, L.P.
		
	By:	 	NEA General Partners, L.P.
		 	Its General Partner
		
	By:	 	 /s/ C. Richard Kramlich

	Name:	 	C. Richard Kramlich
	Title:	 	General Partner
		
	Address:	 	 2800 Sand Hill Road
 Menlo Park, CA
94025

	
	NEA VENTURES 1997, LIMITED PARTNERSHIP
		
	By:	 	 /s/ Diane N. Williams

	Name:	 	Diane N. Williams
	Title:	 	Vice President
		
	Address:	 	 2800 Sand Hill Road
 Menlo Park, CA
94025











			
	 PIPER JAFFRAY HEALTHCARE FUND II
 LIMITED
PARTNERSHIP

		
	By	 	Piper Jaffray Healthcare Management
		 	Limited Partnership,
		 	its General Partner
		
	By:	 	 /s/ Edwin F. Scheetz III

		 	Edwin F. Scheetz III,
		 	Vice President of
		 	Piper Jaffray Ventures, Inc.,
		 	its General Partner
		
	Address:	 	 Piper Jaffray Ventures, Inc.
 100 Spear Street, Suite
1600
 San Francisco, CA 94105











			
	VERTICAL FUND I, L.P.
		
	By	 	Vertical Group, L.P., General Partner
		
	By:	 	 /s/ Stephen D. Baksa

	Name:	 	Stephen D. Baksa
	Title:	 	President
		
	Address:	 	 25 DeForest Avenue
 Summit, NJ 07901

	
	VERTICAL FUND II, L.P.
		
	By	 	Vertical Group, L.P., General Partner
		
	By:	 	 /s/ Stephen D. Baksa

	Name:	 	Stephen D. Baksa
	Title:	 	President
		
	Address:	 	 25 DeForest Avenue
 Summit, NJ 07901











			
	MPM BIOVENTURES II, L.P.
		
	By:	 	MPM Asset Management II, L.P.,
		 	its General Partner
		
	By:	 	MPM Asset Management II LLC,
		 	its General Partner
		
	By:	 	 /s/ Kurt Wheeler

	Name:	 	Kurt C. Wheeler
	Title:	 	Investment Manager
		
	Address:	 	 111 Huntington Avenue
 31st Floor
 Boston, MA 02199

	
	MPM BIOVENTURES II-QP, L.P.
		
	By:	 	MPM Asset Management II, L.P.,
		 	its General Partner
		
	By:	 	MPM Asset Management II LLC,
		 	its General Partner
		
	By:	 	 /s/ Kurt Wheeler

	Name:	 	Kurt C. Wheeler
	Title:	 	Investment Manager
		
	Address:	 	 111 Huntington Avenue
 31st Floor
 Boston, MA 02199











			
	 MPM BIOVENTURES GMBH & CO.
 PARALLEL-BETEILIGUNGS KG

		
	By:	 	MPM Asset Management II, L.P.,
		 	in its capacity as the
		 	Special Limited Partner
		
	By:	 	MPM Asset Management II LLC,
		 	its General Partner
		
	By:	 	 /s/ Kurt Wheeler

	Name:	 	Kurt C. Wheeler
	Title:	 	Investment Manager
		
	Address:	 	 111 Huntington Avenue
 31st Floor
 Boston, MA 02199

	
	 MPM ASSET MANAGEMENT INVESTORS
 2000 B
LLC

		
	By:	 	 /s/ Kurt Wheeler

	Name:	 	Kurt C. Wheeler
	Title:	 	Investment Manager
		
	Address:	 	 111 Huntington Avenue
 31st Floor
 Boston, MA 02199











			
	CYCAD GROUP, LLC
		
	By:	 	 /s/ K. Leonard Judson

	Name:	 	K. Leonard Judson
	Title:	 	President and Manager
		
	Address:	 	 6187 Carpinteria Avenue,
 Suite 300
 P.O. Box 5010
 Carpentaria, CA 93014

	
	ev3 INC.
		
	By:	 	 /s/ Jim Corbett

	Name:	 	Jim Corbett
	Title:	 	CEO
		
	Address:	 	 c/o Jim Corbett
 1861 Buerkle Road
 White Bear, MN 55110











			
	  

	Stephen Corday, M.D.
		
	Address:	 	 Cedars-Sinai Medical Towers
 8635 W. Third St. #790
West
 Los Angeles, CA 90048

	
	THE CORDAY LIVING TRUST
	
	  

	Marion Corday, Trustee
		
	Address:	 	 810 N. Roxbury Drive
 Beverly Hills CA
90210-3018

	
	ELIOT CORDAY RESEARCH FOUNDATION
		
	By:	 	  

	Name:	 	  

	Title:	 	  











			
	UNICORN MEDICAL INCORPORATED
		
	By:	 	 /s/ P Gobin

	Name:	 	Y P Gobin
	Title:	 	CEO
		
	Address:	 	 c/o Pierre Gobin, M.D.,
 Department of
Radiology
 Cornell University
 525 E. 68th Street
 Box 141
 New York, NY 10021

	
	PAMALION
		
	By:	 	 /s/ P Gobin

	Name:	 	Y P Gobin
	Title:	 	Illegible
		
	Address:	 	 c/o Pierre Gobin, M.D.,
 Department of
Radiology
 Cornell University
 525 E. 68th Street
 Box 141
 New York, NY 10021

		
		 	 /s/ P Gobin

		 	Yves P. Gobin, MD
		
	Address:	 	 6 Cayuga Trail
 Harrison, NY 10528











			
	THE FEFFER OLINS FAMILY TRUST
		
		 	 /s/ Ethan D. Feffer

		 	Ethan D. Feffer, Trustee
		
	Address:	 	 8 Tidal Surf
 Newport Coast, CA
92657











			
	 THE R. DAVID COLLIN TRUST DATED
 MARCH 17,
1999

		
		 	 /s/ R. David Collin

		 	R. David Collin, Trustee
		
	Address:	 	 579 N.E. Plantation Road
 #307-8 South
 Stuart, FL 34996











			
	DAVID C. CORNETT AND CHRISTINE
	E. CORNETT, TRUSTEES OF THE CORNETT FAMILY TRUST U/D/T 1/15/86
		
	By:	 	 /s/ David C. Cornett /s/ Christine E. Cornett

	Name:	 	David C. Cornett Christine E. Cornett
	Title:	 	Trustees
		
	Address:	 	 2339 Port Carlisle Place
 Newport Beach, CA
92660

	
	ARTHUR P. CODLING, TRUSTEE OF THE JOSHUA PAYNE CORNETT 1986 TRUST UTA 1/15/86
		
	By:	 	 /s/ Arthur P. Codling

	Name:	 	Arthur P. Codling
	Title:	 	Trustee
		
	Address:	 	 2339 Port Carlisle Place
 Newport Beach, CA
92660

	
	ARTHUR P. CODLING, TRUSTEE OF THE TODD COLLINS CORNETT 1986 TRUST UTA 1/15/86
		
	By:	 	 /s/ Arthur P. Codling

	Name:	 	Arthur P. Codling
	Title:	 	Trustee
		
	Address:	 	 2339 Port Carlisle Place
 Newport Beach, CA
92660











					
		 	 /s/ R. Austin Williams III
	 	
		 	R. Austin Williams, III	 	
			
	Address:	 	2683 Green Street	 	
		 	San Francisco, CA 94123-4606	 	
			
		 	 /s/ Reid Alexander Williams
	 	
		 	Reid Alexander Williams	 	
			
	Address:	 	13 Vandam Street	 	
		 	New York, NY 10013	 	
			
		 	 /s/ R. A. Williams, Jr.
	 	
		 	Raymond A. Williams, Jr.	 	
			
	Address:	 	1960 Webster Street	 	
		 	Palo Alto, CA 94301	 	










			
	 THE WOOD FAMILY TRUST, DATED
 AUGUST 14,
1998

		
		 	 /s/ Jeffrey G. Wood

		 	Jeffrey G. Wood, Co Trustee
		
	Address:	 	 Wall Street Property Company
 567 San Nicolas Drive,
Suite
 207 Newport Beach, CA 92660










 EXHIBIT A TO INVESTOR RIGHTS AGREEMENT 
 (This list does not reflect the conversion of certain shares of Preferred Stock into Common Stock as a result of the investment participation requirements of the Company’s Series F Preferred Stock Financing. This
list reflects pre-split shares for all classes and series of stock except the Series F Preferred Stock, which reflects post-split shares.) 
  

			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 Advent Atlantic & Pacific, L.P.
	  	 3,353 Common

	 by TA Associates
	  	
	 Attn: Katherine S. Cromwell
	  	
	 125 High Street
	  	
	 Suite 2500
	  	
	 Boston, MA 02110
	  	
		
	 Advent Capital, Ltd.
	  	 873 Common

	 by Advent International Corporation, General Partner
	  	
	 Attn: Paal Gisholt
	  	
	 101 Federal Street
	  	
	 Boston, MA 02110
	  	
		
	 Advent Chestnut II, L.P.
	  	 1,729 Common

	 by TA Associates
	  	
	 Attn: Katherine S. Cromwell
	  	
	 125 High Street
	  	
	 Suite 2500
	  	
	 Boston, MA 02110
	  	
		
	 Advent Industrial, L.P.
	  	 997 Common

	 by TA Associates
	  	
	 Attn: Katherine S. Cromwell
	  	
	 125 High Street
	  	
	 Suite 2500
	  	
	 Boston, MA 02110
	  	
		
	 Advent International Investors, L.P.
	  	 41 Common

	 by Advent International Corporation, General Partner
	  	
	 Attn: Paal Gisholt
	  	
	 101 Federal Street
	  	
	 Boston, MA 02110
	  	
		
	 Advent V, L.P.
	  	 6,248 Common

	 by TA Associates
	  	
	 Attn: Katherine S. Cromwell
	  	
	 125 High Street
	  	
	 Suite 2500
	  	
	 Boston, MA 02110
	  	
		
	 Amerivest, Inc.
	  	 118 Common

	 Private Equity Investors
	  	
	 Attn: Charles Stetson, Jr.
	  	
	 115 E. 62nd Street
	  	
	 New York, NY 10021
	  	









			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 Robert K. Anderson
	  	 21,609 Common

	 8070 N. Coconino Road
	  	
	 Paradise Valley, AZ 85253
	  	
		
	 Donald S. Baim, M.D.
	  	 16 Common

	 31 Beethoven Avenue
	  	 2,000 Series A

	 Newton, MA 02168-1732
	  	
		
	 Margaret A. Baim
	  	 16 Common

	 9 Anthony Road
	  	 2,000 Series A

	 Wayland, MA 01778
	  	 161 Series F

		
	 Ellen S. Bancroft
	  	 2,415 Series E

	 6 South View
	  	 194 Series F

	 Coto de Caza, CA 92679
	  	 292 Series F

		
	 Jacques Berland
	  	 32 Common

		
	 Karen Blackfield
	  	 2,894 Common

	 1046 Selby Avenue
	  	 22,220 Series A

	 Los Angeles, CA 90024
	  	
		
	 Morris Blank
	  	 149 Common

	 865 Comstock Drive
	  	
	 Los Angeles, CA 90024
	  	
		
	 The Harold and Jeanne Bloom Family Trust
	  	 150 Common

	 By Its Successor Trustees
	  	
	 Barbara Bloom
	  	
	 809 N. Harper Avenue
	  	
	 Los Angeles, CA 90046
 and
	  	
	 Lisa Bloom
	  	
	 27155 Baxard Place
	  	
	 Valencia, CA 92354
	  	
		
	 Bost & Co.
	  	 1,533 Common

	 (Nominee Name for Chestnut Capital International II)
	  	
	 By TA Associates
	  	
	 Attn: Katherine S. Cromwell
	  	
	 125 High Street
	  	
	 Suite 2500
	  	
	 Boston, MA 02110
	  	
		
	 Boston Safe Deposit and Trust Company as Trustee for
	  	 303 Common

	 US WEST Master Trust
	  	
	 Attn: Ms. Christina Cantu
	  	
	 1 Cabot Road
	  	
	 Medford, MA 02155-5160
	  	
		
	 Brobeck, Phleger & Harrison LLP
	  	 12,077 Series E

	 38 Technology Drive
	  	
	 Irvine, CA 92618
	  	









			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 Channel Medical Partners, L.P.
	  	 666,667 Series F

	 5750 Old Orchard Road, Suite 310
	  	
	 Skokie, IL 60077
	  	
		
	 Robert D. Clark
	  	 1,538 Common

	 2345 N. Green Valley Parkway
	  	
	 Suite 318
	  	
	 Henderson, NV 89014
	  	
		
	 Robert D. and Beverly S. Clark,
	  	 6,750 Common

	 as Community Property
	  	 12,000 Series A

	 2245 N. Green Valley Parkway
	  	 5,835 Series B

	 Suite 318
	  	
	 Henderson, NV 89014
	  	
		
	 Canaan Equity II L.P.
	  	 1,289,040 Series F

	 105 Rowayton Avenue
	  	
	 Rowayton, CT 06853
	  	
		
	 Canaan Equity II L.P. (QP)
	  	 576,624 Series F

	 105 Rowayton Avenue
	  	
	 Rowayton, CT 06853
	  	
		
	 Canaan Equity II Entrepreneurs LLC
	  	 102,336 Series F

	 105 Rowayton Avenue
	  	
	 Rowayton, CT 06853
	  	
		
	 PaineWebber FBO Robert D. Clark
	  	 3,000 Common

	 50 W. San Fernando
	  	
	 Suite 800
	  	
	 San Jose, CA 95113
	  	
		
	 CMI Ventures
	  	 31 Common

	 c/o Stephen Hagen
	  	
	 1436 Hamilton Avenue
	  	
	 Palo Alto, CA 94301
	  	
		
	 R. David Collin, Trustee under
	  	 30,180 Common

	 R. David Collin Trust
	  	 90,000 Series A

	 579 NE Plantation Road
	  	 23,341 Series B

	 #307-8 South
	  	 13,517 Series F

	 Stuart, Florida 34996
	  	
		
	 Webster Street Fund
 c/o David Collin
	  	
	 4 Thackery Lane
	  	
	 Mendham, NJ 07945
	  	
		
	 Wayne Combs
	  	 364 Common

	 600 E. Weddell Drive #23
	  	 2,000 Series A

	 Sunnyvale, CA 94089
	  	









			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 Marion Corday, Trustees of
	  	 302,089 Common

	 The Corday Living Trust
	  	 224,000 Series A

	 810 N. Roxbury Drive
	  	 136,158 Series B

	 Beverly Hills, CA 90210
	  	
		
	 The Eliot Corday Research Foundation
	  	 9,278 Common

	 c/o Eliot Corday
	  	 163,239 Series B

	 810 N. Roxbury Drive
	  	
	 Beverly Hills, CA 90210
	  	
		
	 Stephen Corday, M.D.
	  	 43,192 Common

	 Cedars-Sinai Medical Towers
	  	 5,489 Series B

	 8635 W. Third St. #790 West
	  	 30 Series F

	 Los Angeles, CA 90048
	  	
		
	 Arthur P. Codling, Trustee of
	  	 1,127 Common

	 the Joshua Payne Cornett 1986
	  	 40,000 Series A

	 Trust UTA 1/15/86
	  	 5,161 Series F

	 2339 Port Carlisle Place
	  	
	 Newport Beach, CA 92660
	  	
		
	 Arthur P. Codling, Trustee of
	  	 1,127 Common

	 the Todd Collins Cornett 1986
	  	 40,000 Series A

	 Trust UTA 1/15/86
	  	 11,828 Series F

	 2339 Port Carlisle Place
	  	
	 Newport Beach, CA 92660
	  	
		
	 David C. Cornett and Christine C. Cornett, Trustees
	  	 45,727 Common

	 of the Cornett Family Trust U/D/T 1/15/86
	  	 75,000 Series A

	 2339 Port Carlisle Place
	  	 9,677 Series F

	 Newport Beach, CA 92660
	  	
		
	 Timothy Cortez
	  	 7 Common

	 2870 Kilgore Road
	  	
	 Rancho Cordova, CA 95670
	  	
		
	 Suzanne P. Cummings Trust U/D/T dated 7/12/87
	  	 5,472 Common

	 806 North Camden Drive
	  	
	 Beverly Hills, CA 90210
	  	
		
	 Cycad Group, LLC
	  	 60,750 Common

	 c/o K. Leonard Judson, Esq.
	  	 111,108 Series A

	 1250 Coast Village Road
	  	 51,445 Series B

	 Suite K
	  	 57,283 Series E

	 Santa Barbara, CA 93108-2720
	  	 116,084 Series F

		  	43,912 Series F
	 Lauri Deyhiny (Fischer)
	  	 724 Series E

		
	 J. Kevin Drury
	  	 125 Common

	 8631 W. Third Street
	  	
	 Los Angeles, CA 90048
	  	









			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 Dieter Enzmann
	  	 172 Common

	 Chairman, Department of Radiology
	  	
	 Northwestern University
	  	
	 222 E. Superior, Ste 140
	  	
	 Chicago, IL 60611
	  	
		
	 Susan Enzmann
	  	 172 Common

	 c/o Dieter Enzmann, M.D.
	  	
	 Chairman, Department of Radiology
	  	
	 Northwestern University
	  	
	 222 E. Superior, Ste 140
	  	
	 Chicago, IL 60611
	  	
		
	 ev3 Inc.
	  	 3,864,734 Series E

	 c/o Jim Corbett
	  	 208,340 Series F

	 1861 Buerkle Road
	  	
	 White Bear Lake, MN 55110
	  	
		
	 Scott M. Evans
	  	 1,000 Series A

	 1152 Country Hill Drive
	  	
	 Santa Ana, CA 92705
	  	
		
	 Sidney L. Evans
	  	 1,000 Series A

	 8701 East Sells Drive
	  	
	 Scottsdale, AZ 85251
	  	
		
	 Jean Farcot, M.D.
	  	 125 Common

	 39 Rue Spontini
	  	
	 Paris, 75116
	  	
	 France
	  	
		
	 The Feffer Olins Family Trust
	  	 2,595 Series E

	 Attn: Ethan Feffer, Trustee
	  	 310 Series F

	 8 Tidal Surf
	  	 292 Series F

	 Newport Coast, CA 92657
	  	
		
	 Fever Trust
	  	 422,706 Series E

	 2800 Sand Hill Road
	  	
	 Menlo Park, CA 94025
	  	
		
	 Fever Trust II
	  	 15,938 Series E

	 2800 Sand Hill Road
	  	
	 Menlo Park, CA 94025
	  	
		
	 Fever Trust III
	  	 65,018 Series F

	 2800 Sand Hill Road
	  	
	 Menlo Park, CA 94025
	  	
		
	 Stephen R. Finn
	  	 4,830 Series E

	 P.O. Box 1491
	  	 387 Series F

	 San Mateo, CA 94401
	  	 292 Series F










			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 Craig J. Foley
	  	 13 Common

	 Wickham Capital Corp.
	  	
	 7 Locust Lane
	  	
	 Bronxville, NY 10708
	  	
		
	 Marie T. Frisbie
	  	 150 Common

	 3230 Maple Leaf Court
	  	
	 San Jose, CA 95121
	  	
		
	 Pierre Gobin M.D.
	  	 19,355 Series C-D

	 Department of Radiology
	  	 19,323 Series E

	 Cornell University
	  	 8,333 Series F

	 525 E. 68th Street, Box 141
	  	
	 New York, NY 10021
	  	
		
	 Goodman Co., Ltd.
	  	 1,046 Common

	 16421-D Gothard Avenue
	  	
	 Attn: Akira Yamamoto
	  	
	 Huntington Beach, CA 92647
	  	
		
	 Guidant Corporation
	  	 621,746 Series C-D

	 135 Constitution Drive
	  	 1,124,617 Series C-D

	 Menlo Park, CA 94025
	  	
		
	 Hank & Co. (nominee name for Citibank, N.A.,
	  	 241 Common

	 as Custodian for Citicare at the direction of
	  	
	 Chancellor Capital Management, Inc., Investment Manager)
	  	
	 UNKNOWN (No longer a Chancellor client)
	  	
		
	 Health Care Ventures, Inc.
	  	 37,923 Common

	 c/o Robert K. Anderson
	  	
	 8070 N. Coconino Road
	  	
	 Paradise Valley, AZ 85283
	  	
		
	 Jay C. Hoag
	  	 3 Common

	 Technology Crossover Ventures
	  	
	 575 High Street
	  	
	 Suite 400
	  	
	 Palo Alto, CA 94301
	  	
		
	 Harold C. Hohbach
	  	 749 Common

	 29 Lowery Drive
	  	
	 Atherton, CA 94025
	  	
		
	 Hutton Living Trust dated 12/10/96
	  	 25,122 Series E

	 2 Santiago Avenue
	  	 2,996 Series F

	 Atherton, CA 94027
	  	 20,000 Series F

		
	 Jerome Jackson
	  	 280 Common

	 1725 Fallen Leaf Lane
	  	
	 Los Altos, CA 94024
	  	









			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 Kaneko Enterprises, Inc.
	  	 6,771 Common

	 16421-D Gothard Avenue
	  	
	 Attn: Masahiko Kaneko
	  	
	 Huntington Beach, CA 92647
	  	
		
	 Sheila Kar
	  	 2,000 Common

	 510 South Burnside Avenue #5J
	  	
	 Los Angeles, CA 90036
	  	
		
	 Gregory Kopchinsky
	  	 8,333 Series F

	 105 Rowayton Avenue
	  	
	 Rowayton, CT 06853
	  	
		
	 Anthony R. Kozberg
	  	 8,501 Common

	 721 North Linden Drive
	  	
	 Beverly Hills, CA 90210
	  	
		
	 Lindsey C. Kozberg
	  	 11,834 Common

	 721 North Linden Drive
	  	
	 Beverly Hills, CA 90210
	  	
		
	 Joanne Corday Kozberg
	  	 23,937 Common

	 721 North Linden Drive
	  	 1,324 Series A

	 Beverly Hills, CA 90210
	  	
		
	 Joanne C. Kozberg, Custodian for Anthony R. Kozberg
	  	 3,685 Common

	 721 North Linden Drive
	  	 220 Series A

	 Beverly Hills, CA 90210
	  	
		
	 Joanne C. Kozberg, Custodian for Lindsey C. Kozberg
	  	 351 Common

	 721 North Linden Drive
	  	 220 Series A

	 Beverly Hills, CA 90210
	  	
		
	 Roger A. Kozberg
	  	 701 Common

	 721 North Linden Drive
	  	 440 Series A

	 Beverly Hills, CA 90210
	  	
		
	 Tsu Lang
	  	 63 Common

	 301 North Elm Drive
	  	
	 Beverly Hills, CA 90210
	  	
		
	 Christian Lundquist
	  	 1,052 Common

	 271 Sundown Terrace
	  	
	 Orinda, CA 94563
	  	
		
	 Ingemar H. Lundquist
	  	 6,313 Common

	 P.O. Box 1186
	  	
	 Pebble Beach, CA 93953
	  	
		
	 Richard H. Lundquist
	  	 188 Common

	 c/o Ingemar H. Lundquist
	  	
	 P.O. Box 1186
	  	
	 Pebble Beach, CA 93953
	  	









			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 Mayfield VIII
	  	 940,264 Series C-D

	 2800 Sand Hill Road
	  	 2,440,769 Series C-D

	 Menlo Park, CA 94025
	  	 936,685 Series C-D

		  	 481,427 Series E

		  	 756,404 Series F

		
	 Mayfield Associates Fund III
	  	 49,488 Series C-D

	 2800 Sand Hill Road
	  	 128,463 Series C-D

	 Menlo Park, CA 94025
	  	 49,299 Series C-D

		  	 25,339 Series E

		  	 39,810 Series F

		
	 Medtronic, Inc.
	  	 54,000 Common

	 710 Medtronic Parkway
	  	 535,452 Series A

	 Minneapolis, MN 55432
	  	 301,299 Series B

		  	 994,706 Series C-D

		  	 340,071 Series C-D

		  	 415,459 Series E

		
	 Medtronic Asset Management, Inc.
	  	 270,000 Common

	 710 Medtronic Parkway
	  	
	 Minneapolis, MN 55432
	  	
		
	 Mellon Bank, N.A.
	  	 19 Common

	 Master Trustee for Bell Atlantic Master Trust
	  	
	 (as directed by Chancellor Capital Management, Inc.,
	  	
	 Investment Manager)
	  	
	 UNKNOWN (No longer a Chancellor client)
	  	
		
	 Mellon Bank, N.A.
	  	 303 Common

	 Master Trustee for Bell Atlantic Master Trust
	  	
	 (as directed by Citibank, N.A., Investment Manager)
	  	
	 UNKNOWN (No longer a Chancellor client)
	  	
		
	 Jerry Mezger
	  	 1,000 Series A

	 Endicor Medical, Inc.
	  	 80 Series F

	 5441 Avenida Encinas
	  	
	 Suite A
	  	
	 Carlsbad, CA 92008
	  	
		
	 MPM Bioventures II, L.P.
	  	 565,494 Series E

	 c/o Kurt Wheeler
	  	 199,886 Series F

	 111 Huntington Avenue
	  	
	 31st Floor
	  	
	 Boston, MA 02199
	  	
		
	 MPM Bioventures II-QP, L.P.
	  	 5,123,691 Series E

	 c/o Kurt Wheeler
	  	 1,811,086 Series F

	 111 Huntington Avenue
	  	
	 31st Floor
	  	
	 Boston, MA 02199
	  	









			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 MPM Bioventures GMBH & Co. Parallel-Beteiligungs KG
	  	 1,803,795 Series E

	 c/o Kurt Wheeler
	  	 637,592 Series F

	 111 Huntington Avenue
	  	
	 31st Floor
	  	
	 Boston, MA 02199
	  	
		
	 MPM Asset Management Investors 2000 B LLC
	  	 117,970 Series E

	 c/o Kurt Wheeler
	  	 41,699 Series F

	 111 Huntington Avenue
	  	
	 31st Floor
	  	
	 Boston, MA 02199
	  	
		
	 New Enterprise Associates VII, Limited Partnership
	  	 933,047 Series C-D

	 2490 Sand Hill Road
	  	 2,569,232 Series C-D

	 Menlo Park, CA 94025
	  	 985,984 Series C-D

		  	 1,009,501 Series E

		  	 844,489 Series F

		
	 NEA Presidents Fund, L.P.
	  	 51,550 Series C-D

	 2490 Sand Hill Road
	  	
	 Menlo Park, CA 94025
	  	
		
	 NEA Ventures 1997, Limited Partnership
	  	 5,155 Series C-D

	 2490 Sand Hill Road
	  	
	 Menlo Park, CA 94025
	  	
		
	 Pamalion
	  	 60,000 Series F

	 c/o Paul Gobin, M.D.
	  	
	 21, rue du Chateau
	  	
	 77310 Boissise-Le-Roi, France
	  	
		
	 Pantheon USA Fund Limited
	  	 244 Common

	 Attn: Ian Deas
	  	
	 50 California Street, Suite 906
	  	
	 San Francisco, CA 94111
	  	
		
	 Karen & Noel Peterkin
	  	 152 Common

	 4730 Galice Road
	  	
	 Merlin, OR 97532
	  	
		
	 Piper Jaffray Healthcare Fund II Limited Partnership
	  	 1,384,616 Series C-D

	 Piper Jaffray Ventures, Inc.
	  	 417,224 Series C-D

	 100 Spear Street, Suite 1600
	  	 347,827 Series E

	 San Francisco, CA 94105
	  	 290,805 Series F

		
	 Pitt & Co.
	  	 321 Common

	 c/o Bankers Trust Company
	  	
	 GFS/CTAG Bin #4 Window #43
	  	
	 16 Wall Street - 4th Floor
	  	
	 Attn: Joycelyn Frett
	  	
	 New York, NY 10005
	  	
		
	 Lavergne Poe
	  	 125 Common

	 P.O. Box 620096
	  	
	 Woodside, CA 94062
	  	









			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 David C. Pound
	  	 808 Common

	 24831 Weyburn
	  	
	 Laguna Hills, CA 92653
	  	
		
	 Private Equity Investment Fund, L.P.
	  	 17 Common

	 Attn: Charles Stetson, Jr.
	  	
	 115 E. 62nd Street
	  	
	 New York, NY 10021
	  	
		
	 Richard and Lori Randall
	  	 3,000 Series A

		
	 Natasha Reiss, under GUGMA
	  	 32 Common

	 Until age 18
	  	
		
	 Tanya Reiss
	  	 32 Common

		
	 Reiss Family Trust U/D/T
	  	 63 Common

	 Dated 12/19/88
	  	
		
	 Rovent Limited Partnership
	  	 3,062 Common

	 By Advent International Limited Partnership, General Partner
	  	
	 By Advent International Corporation, General Partner
	  	
	 Attn: Paal Gisholt
	  	
	 101 Federal Street
	  	
	 Boston, MA 02110
	  	
		
	 Dr. Seth Rudnick
	  	 12,000 Series F

	 105 Rowayton Avenue
	  	
	 Rowayton, CT 06853
	  	
		
	 Saturn & Co. TID04-2457313
	  	 798 Common

	 by TA Associates
	  	
	 Attn: Katherine S. Cromwell
	  	
	 125 High Street
	  	
	 Suite 2500
	  	
	 Boston, MA 02110
	  	
		
	 Parag Saxena
	  	 5 Common

	 Chancellor Capitol Management, Inc.
	  	
	 Managing Director
	  	
	 1166 Avenue of the Americas
	  	
	 Attn: Mark Radovanovich
	  	
	 New York, NY 10036
	  	
		
	 Sequoia Capital IV
	  	 33,872 Common

	 c/o Sequoia Technology Partners
	  	
	 Building 4, Suite 280
	  	
	 3000 Sand Hill Road
	  	
	 Attn: Gordon Russell
	  	
	 Menlo Park, CA 94025
	  	









			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 Sequoia Technology Partners II
	  	 2,259 Common

	 c/o Sequoia Technology Partners
	  	
	 Building 4, Suite 280
	  	
	 3000 Sand Hill Road
	  	
	 Attn: Gordon Russell
	  	
	 Menlo Park, CA 94025
	  	
		
	 Sequoia XX
	  	 273 Common

	 c/o Sequoia Technology Partners
	  	
	 Building 4, Suite 280
	  	
	 3000 Sand Hill Road
	  	
	 Attn: Gordon Russell
	  	
	 Menlo Park, CA 94025
	  	
		
	 Sequoia XXI
	  	 1,233 Common

	 Building 4, Suite 280
	  	
	 3000 Sand Hill Road
	  	
	 Menlo Park, CA 94025
	  	
		
	 Philip M. Shaw
	  	 2 Common

	 Chancellor Capital Management
	  	
	 1166 Avenue of the Americas
	  	
	 New York, NY 10036
	  	
		
	 Cheryl Shea
	  	 8 Common

		
	 Gloria Sherwood
	  	 131 Common

	 7829 Harbor Town
	  	
	 Las Vegas, NV 89113
	  	
		
	 Stan Shofner
	  	 47 Common

		
	 Nancy A. Shultz
	  	 940 Common

	 35 Calle Maria
	  	 8,000 Series A

	 Rancho Santa Margarita, CA 92688
	  	
		
	 Darline Silk
	  	 2,000 Common

	 Cedars Sinai Medical Towers
	  	
	 8635 W. Third Street, #790 West
	  	
	 Los Angeles, CA 90048
	  	
		
	 Dale Simbro
	  	 3,334 Common

	 1835 Port Carlow Place
	  	
	 Newport Beach, CA 92660
	  	
		
	 Stanford University
	  	 388 Common

	 Stanford Management Office
	  	
	 Attn: Carol Gilmer
	  	
	 2770 Sand Hill Road
	  	
	 Menlo Park, CA 94025
	  	
		
	 Peter K. and Christine Stein, Trustees
	  	 3,584 Common

	 FBO The Stein Family Trust U/A Dated 6/4/84
	  	
	 1340 Fairway Drive
	  	
	 Los Altos, CA 94024
	  	









			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 John L. Stevens
	  	 207 Common

	 835 Panorama Road
	  	 8,000 Series A

	 Fullerton, CA 926831
	  	
		
	 TA Investors
	  	 145 Common

	 By TA Associates
	  	
	 Attn: Katherine S. Cromwell
	  	
	 125 High Street
	  	
	 Suite 2500
	  	
	 Boston, MA 02110
	  	
		
	 Zoltan Tarczy-Hornoch
	  	 1,383 Common

	 2 Commodore Drive, Apt. #475
	  	
	 Emeryville, CA 94608
	  	
		
	 Marc Tesler
	  	 3 Common

	 Technology Crossover Ventures
	  	
	 575 High Street
	  	
	 Suite 400
	  	
	 Palo Alto, CA 94301
	  	
		
	 Phil Thomas
	  	 30,000 Common

	 3 Hazelwood Lane
	  	
	 Smokerise Kinnelon, NJ 07405
	  	
		
	 Unicorn Medical Inc.
	  	 76,924 Series C-D

	 c/o Pierre Gobin, M.D.
	  	 14,492 Series E

	 Department of Radiology
	  	 6,666 Series F

	 Cornell University
	  	
	 525 E. 68th Street, Box 141
	  	
	 New York, NY 10021
	  	
		
	 Vertical Fund I, L.P.
	  	 466,154 Series C-D

	 25 DeForest Avenue
	  	 361,471 Series C-D

	 Summit, NJ 07901
	  	 210,858 Series E

		  	 196,914 Series F

		  	 127,258 Series F

		
	 Vertical Fund II, L.P.
	  	 149,231 Series C-D

	 25 DeForest Avenue
	  	 115,718 Series C-D

	 Summit, NJ 0790
	  	 62,894 Series E

		  	 47,326 Series F

		  	 30,827 Series F

		
	 William Washington
	  	 3 Common

	 2521 Stockport # 172
	  	
	 Laguna Hills, CA 92653
	  	
		
	 Russ Weiner
	  	 483 Series E

		
	 John P. Welsh
	  	 66 Common

	 25108 Marguerite Parkway
	  	
	 #B426
	  	
	 Mission Viejo, CA 92692
	  	
		
	 Mark E. Whitebook
	  	 13,542 Common

	 34661 Calle Rosita
	  	
	 Capistrano Beach, CA 92624-1550
	  	









			
	 NAME & ADDRESS OF INVESTOR
	  	 REGISTRABLE SECURITIES

	 Raymond A. Williams and Carol Bartle Williams
	  	 22,313 Common

	 1960 Webster Street
	  	
	 Palo Alto, CA 94301
	  	
		
	 Raymond A. Williams, Jr.
	  	 225,217 Common

	 1960 Webster Street
	  	 177,776 Series A

	 Palo Alto, CA 94301
	  	 211,228 Series B

		  	 13,300 Series F

		  	 6,733 Series F

		
	 R. Austin Williams, III
	  	 165,610 Common

	 2683 Green Street
	  	 133,332 Series A

	 San Francisco, CA 94123-4606
	  	 131,506 Series B

		  	 8,587 Series F

		  	 4,391 Series F

		
	 Reid Alexander Williams
	  	 165,610 Common

	 13 Vandam Street
	  	 133,332 Series A

	 New York, NY 10013
	  	 131,506 Series B

		  	 8,587 Series F

		  	 4,391 Series F

		
	 Gabrielle M. Wirth
	  	 2,415 Series E

	 38 Technology Drive
	  	 194 Series F

	 Irvine, CA 92618
	  	 292 Series F

		
	 Vivian Wohl
	  	 16 Common

	 Robertson, Stephens & Company
	  	
	 555 California Street, #2600
	  	
	 San Francisco, CA 94104
	  	
		
	 WS Investments 85A
	  	 50 Common

	 Wilson Sonsini Goodrich & Rosati
	  	
	 650 Page Mill Road
	  	
	 Palo Alto, CA 94304
	  	
		
	 WS Investments 86A
	  	 10 Common

	 Wilson Sonsini Goodrich & Rosati
	  	
	 650 Page Mill Road
	  	
	 Palo Alto, CA 94304
	  	
		
	 WS Investments 92B
	  	 22,212 Series A

	 Wilson Sonsini Goodrich & Rosati
	  	
	 650 Page Mill Road
	  	
	 Palo Alto, CA 94304
	  	
		
	 WTI Ventures
	  	 9,415 Common

	 Attn: S. Allan Johnson
	  	
	 1010 Menlo Center, Room 306
	  	
	 Menlo Park, CA 94025
	  	
		
	 The Wood Family Trust,
	  	 20,000 Series F

	 Jeffrey G. Wood, Co Trustee
	  	
	 Wall Street Property Company
	  	
	 567 San Nicolas Drive, Suite 207
	  	
	 Newport Beach, CA 92660
	  	








 EXHIBIT B 
 COUNTERPART TO TENTH AMENDED AND RESTATED INVESTOR 
 RIGHTS AGREEMENT 
 The undersigned hereby agrees to be a party to, and to be bound by the terms and subject to the conditions of, the Tenth Amended and Restated Investor
Rights Agreement, dated as of September     , 2004 (the “Investor Rights Agreement”), by and among the Company and the Investors as an “Investor” thereunder. 
 All capitalized terms not defined herein shall have the meanings set forth in the Investor Rights Agreement. 
 The undersigned has executed this Counterpart to the Investor Rights Agreement as of 9/21, 2004. 
  

			
	 Stephen R. Finn

	(Print name of individual or company)
		
	Sign:	 	 /s/ Stephen R. Finn




			
		
	Title (if applic.):	 	  




			
		
	Address:	 	
	 PO Box 1491
 San Mateo, CA
94401

	Tel. no.:	 	415-309-3073
	Fax no.:	 	415-442-1010









 EXHIBIT B 
 COUNTERPART TO TENTH AMENDED AND RESTATED INVESTOR 
 RIGHTS AGREEMENT 
 The undersigned hereby agrees to be a party to, and to be bound by the terms and subject to the conditions of, the Tenth Amended and Restated Investor
Rights Agreement, dated as of September     , 2004 (the “Investor Rights Agreement”), by and among the Company and the Investors as an “Investor” thereunder. 
 All capitalized terms not defined herein shall have the meanings set forth in the Investor Rights Agreement. 
 The undersigned has executed this Counterpart to the Investor Rights Agreement as of Oct. 1, 2004. 
  

			
	 Gabrielle M. Wirth

	(Print name of individual or company)
		
	Sign:	 	 /s/ Gabrielle M. Wirth




			
		
	Title (if applic.):	 	  




			
		
	Address:	 	
	 38 Technology Drive
 Irvine, CA
92618

	Tel. no.:	 	949 932-3690
	Fax no.:	 	









 EXHIBIT B 
 COUNTERPART TO TENTH AMENDED AND RESTATED INVESTOR 
 RIGHTS AGREEMENT 
 The undersigned hereby agrees to be a party to, and to be bound by the terms and subject to the conditions of, the Tenth Amended and Restated Investor
Rights Agreement, dated as of September     , 2004 (the “Investor Rights Agreement”), by and among the Company and the Investors as an “Investor” thereunder. 
 All capitalized terms not defined herein shall have the meanings set forth in the Investor Rights Agreement. 
 The undersigned has executed this Counterpart to the Investor Rights Agreement as of
                    , 200    . 
  

			
	 Ellen S. Bancroft

	(Print name of individual or company)
		
	Sign:	 	 /s/ Ellen Bancroft




			
		
	Title (if applic.):	 	  




			
		
	Address:	 	
	 6 South View
 Coto de Caza, CA
92679

	Tel. no.:	 	949/ 932-3670
	Fax no.:	 	949/ 932-3601